

Aflac
Cancer & Blood Disorders Center
CHILDREN'S HEALTHCARE OF ATLANTA

EMORY UNIVERSITY

BEST CHILDREN'S HOSPITALS
U.S.News & WORLD REPORT
CANCER
2018-19

Hematology/Oncology Fellowship Program

At the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, we offer three-year fellowships in collaboration with Emory University School of Medicine to qualified, promising physicians. We are dedicated to providing a comprehensive program for training subspecialty fellows in pediatric hematology/oncology.

Our goal

Our goal is to train academically oriented hematologists and oncologists who will be involved in a lifetime of excellence in patient care and teaching, in addition to clinical, translational or basic research. Upon successful completion of our training program, fellows will:

- Have a thorough understanding of the pathophysiology of pediatric hematologic and oncologic disorders.
- Be competent in the clinical diagnosis and management of these disorders.
- Understand clinical trials methodology.
- Excel in a selected research interest. Our program seeks to cultivate and encourage laboratory researchers and clinical investigators.

One of the largest pediatric hematology/oncology fellowship programs in the country

about the program

First-year fellows maintain a continuity clinic one day each week. Second- and third-year fellows have the option of changing clinics to every two weeks and being part of outpatient clinics focused on their specific areas of interest.

Clinical rotations–first year

- Oncology ward service (three months)
- Blood and marrow transplant (BMT)–inpatient/outpatient service (two months)
- Hematology ward (two months)
- Outpatient hematology and subspecialty clinic service (two months)
- Neuro-oncology–inpatient/outpatient service (one month)
- Lab rotation–radiation oncology, hematopathology, flow cytometry, cytogenetics, blood banking and special coagulation (one month total divided into two-week blocks)
- Research exploration (one month total divided into two-week blocks)
- Continuity clinic (one day per week)

Research–second and third year

Second- and third-year fellows are offered a variety of opportunities in clinical, translational and basic research. These opportunities are available at the Aflac Cancer Center and within specific divisions of the Emory University Department of Pediatrics.

We are devoted to training physician-scientists seeking careers in laboratory-based academic pediatric hematology/oncology. Research opportunities are performed in collaboration with faculty at the Winship Cancer Institute of Emory University, Emory School of Public Health, Georgia Institute of Technology, the Yerkes National Primate Research Center and the Centers for Disease Control and Prevention (CDC).

In addition to the laboratory-based research track, we offer a clinical research track for fellows interested in careers as clinical investigators. Fellows interested in clinical research are encouraged to apply for Emory's Master of Science in clinical research (MSCR). We are in a unique position to offer special resources for laboratory and clinical training throughout the fellowship period for extended periods of research time, if required.

We have an individualized scholarship oversight and mentoring committee that guides each fellow through their research experience.

Research–optional fourth year

The fourth year is almost exclusively devoted to research and is available with funding to all fellows. This allows fellows to increase their skills for competitiveness in garnering future K-type or other awards for young investigators. We offer fourth-year subspecialty clinical fellowship positions in neuro-oncology and BMT. The goal of the fellowship programs is to train board-certified and board-eligible pediatric hematology/oncology graduates to effectively evaluate and manage children and teens with blood disorders, as well as benign and malignant tumors. Fellows will also become familiar with clinical and/or basic science research techniques.

PhD Program

In conjunction with the Emory Pediatric Fellowship Program, the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Tech, we offer a unique pathway for pediatric hematology/oncology fellows to pursue a PhD during the research portion of their fellowship.

The goal of this program is to train academically oriented pediatric hematologists and oncologists for a lifetime of excellence in patient care and teaching, while also becoming research scholars with in-depth scientific training and earning a PhD in a biomedical discipline. Our program offers young pediatric hematologists and oncologists the rigorous scientific training necessary for success in today's competitive environment, especially for trainees with limited research backgrounds.

Typical on-call schedule

- Night call takes place at home. Fellows occasionally return to the hospital to evaluate extremely ill or newly diagnosed patients.
- First-year: One in four weeknights and one weekend per month
- Second-year: Three to four weeknights and one weekend every one to two months
- Third-year: One to two weeknights per month and one weekend every six months

Didactic schedule

A variety of conferences and seminars are offered. A sample schedule is listed below. Additionally, structured teaching, ethics and research overview courses are offered throughout the year.

	Monday	Tuesday	Wednesday	Thursday	Friday
A.M.		Core curriculum review	Grand rounds		Patient care conference
P.M.		Research conference	Tumor board		

Additional benefits of the program

Fellows receive three weeks of vacation each year. Each fellow has an educational stipend that may be used for meetings, journals or other educational expenses. Senior fellows attend additional scientific meetings based on research presentations.

Accreditation

Our program has been accredited since the 1980s and recieved accreditation in 2004 by the Accreditation Council for Graduate Medical Education. The Aflac Cancer Center is affiliated with Emory University, which is ranked among the top research medical schools in the country by U.S. News & World Report.

Funding

Fellows are fully funded during the three-year program. Additional years of research training, including application for the MSCR program, are available for qualified candidates.

Current fellows

First-year fellows

Holly Edington, MD
holly.edington@choa.org
College: University of North Carolina
Medical school: University of Toledo
Residency: Eastern Virginia Medical School and Children's Hospital of The King's Daughters
"After interviewing at a variety of programs, the Aflac Cancer Center and Emory stood out to me as the best of the best in all the categories that were important to me. The program offers high patient volume, excellent patient care, limitless learning and research opportunities, a positive work-life balance and excellent faculty dedicated to fellowship mentoring."

Diana Fridlyand, MD
diana.fridlyand@choa.org
College: Emory University
Medical school: Medical College of Georgia
Residency: Children's Hospital of Georgia and Medical College of Georgia
"Training at the Aflac Cancer Center and Emory is a great choice for many reasons. The program provides equally strong opportunities to care for kids within our hematology/oncology, and BMT divisions. Research opportunities are abundant at the Aflac Cancer Center, Emory, Winship Cancer Institute and Georgia Tech. Most importantly, everyone is collegial, supportive and excited to train and mentor fellows."

Julie Gilbert, MD
julie.gilbert@choa.org
College: Yeshiva University
Medical school: Albert Einstein College of Medicine
Residency: Montefiore Medical Center
"I chose to train at the Aflac Cancer Center and Emory because they have one of the largest comprehensive hematology/oncology programs in the country, and with endless opportunities for fellows to be involved in clinical and basic research."

Juhi Jain, MD
juhi.jain@choa.org
College: University of Washington Seattle
Medical school: University of Miami Miller School of Medicine
Residency: Baylor College of Medicine and Texas Children's Hospital
"This program offers a breadth of training and research experiences that span the spectrum of hematology/oncology pathophysiology, while also working in a positive, welcoming work environment to advocate for our patients on a daily basis and provide the best care possible."

Pratik "Tik" Patel, MD
pratik.patel@choa.org
College: University of Virginia
Medical school: University of Virginia
Residency: University of Texas Southwestern Dallas
"I chose the Aflac Cancer Center and Emory for a number of reasons, including an excellent balance and strength in hematology/oncology, a large program with great opportunities in basic and clinical research, the fellow camaraderie seemed strong and Atlanta is a lot of fun with things to do both indoors and outdoors."

Second-year fellows

Megan Brown, MD
megan.brown@choa.org
College: Michigan State University
Medical school: Michigan State University
Residency: Children's Hospital Colorado
"I chose the Aflac Cancer Center and Emory for a variety of reasons. The clinical exposure and full breadth of hematologic and oncologic conditions is unmatched, and there are limitless opportunities for research and academic pursuits regardless of your field of interest. Additionally, the program leadership truly values and prioritizes fellow development and education, and the entire department is collegial and supportive with a strong focus on providing the highest quality care to our patients."

Christina Caruso, MD
christina.caruso@choa.org
College: Boston College
Medical school: Creighton University
Residency: North Shore-Long Island
"It is important to me that I train at a large academic institution that is equally dedicated to and strong in hematology/oncology, and I have definitely found that at the Aflac Cancer Center and Emory."

Amanda MacGregor Harrington, MD
amanda.harrington@choa.org
College: University of Georgia
Medical school: Medical College of Georgia
Residency: Tufts Medical Center
"I chose the Aflac Cancer Center and Emory because I knew it was one of the best programs in the country and would offer me a wealth of learning opportunities. Equally as important, I chose the Aflac Cancer Center and Emory because of the people who work here. I felt like this would be a place that I could thrive surrounded by people who love what they do and are always striving to provide excellent patient care. Between high patient volume, a structured learning environment with commitment to fellow education and a supportive faculty with leading experts in the field, I knew this was the right program for me."

Rafi Kazi, MD
rafi.kazi@choa.org
College: Harvard University
Medical school: University of Arkansas
Residency: University of Rochester
"I was excited by the broad clinical opportunities and the strong research program. Also, everyone was very nice."

Anthony Ross, MD
anthony.ross@choa.org
College: Duquesne University
Medical school: University of Pittsburgh
Residency: Children's Hospital of Pittsburgh
"I chose the Aflac Cancer Center and Emory for their well-rounded hematology/oncology training, as well as its dedication to excellent patient care and cutting-edge research."

Third-year fellows

Ashley Eason, MD
ashley.eason@choa.org
College: University of Georgia
Medical school: Mercer University
Residency: University of Virginia
"When applying for a fellowship, I wanted to find a program that was strong in hematology/oncology that also provided ample research opportunities. During my first few months, the Aflac Cancer Center and Emory have provided that and more with supportive faculty, engaging teaching sessions and broad clinical exposure."

Dan Runco, MD
daniel.runco@choa.org
College: Creighton University
Medical school: Loyola University Chicago Stritch School of Medicine
Residency: Riley Hospital for Children at Indiana University Health
"The Aflac Cancer Center and Emory have the best of all worlds and this program pushes you to develop and pursue your own interests—not to fit into someone else's mold. There are clinical and research opportunities in all aspects of hematology/oncology and I felt like if I trained here, there was no door that was closed to me."

Jenny Shim, MD
jenny.shim@choa.org
College: Siena College
Medical school: Albany Medical College
Residency: University of Texas Southwestern Dallas Medical Center
"What I love about the Aflac Cancer Center and Emory are their infinite potential to grow and the fact that it continues to grow in patient care and research. We have a wonderful faculty group that provides well-rounded and personal mentorship. The research opportunities and career development with fourth-year support in hematology/oncology is invaluable."

Sherri Smart, MD, PhD
sheri.smart@choa.org
College: University of Central Arkansas
Medical school: University of Arkansas
Residency: University of Cincinnati
"The Aflac Cancer Center and Emory are a strong academic center with equal focus in hematology/oncology and ample research opportunities in clinical, translational and basic science. During my interview, the biggest thing that stood out in my mind was how happy the fellows, faculty and staff were. I can tell you now that what you see on the surface holds true. We truly are a family."

Michael White, MD
michael.white@choa.org
College: Harding University
Medical school: University of Texas Southwestern Medical School
Residency: Vanderbilt University
"I chose to train at the Aflac Cancer Center and Emory because they are one the largest and most robust hematology/oncology centers in the country and the people here are top-notch. The research and professional opportunities are endless here, and I could not feel more supported by our leadership. I'm thrilled to be in Atlanta."

our center

About our program

As one of the leading pediatric cancer, hematology and BMT programs in the country, the Aflac Cancer Center provides advanced diagnostic and clinical care, educational programs, psychosocial support, and innovative treatment and research options for children and young adults. In addition, we offer exceptional pediatric imaging, surgical and subspecialty support.

Our multidisciplinary approach to care integrates the efforts of many pediatric professionals, including a 33-member family support team composed of nurses, pharmacists, nurse practitioners, nutritionists, child life specialists, social workers, psychologists, chaplains and hospital teachers.

Population served

As one of the largest childhood cancer and blood disorders centers in the country, the Aflac Cancer Center cares for more than 450 newly diagnosed cancer patients each year and sees more than 5,000 patients with sickle cell disease, hemophilia and other blood disorders. In addition, we have performed more than 1,000 BMTs since our program's inception in 1985 and follow more than 1,600 childhood cancer survivors.

Facility features

The Aflac Cancer Center features:

- 64 inpatient beds across the Egleston and Scottish Rite hospital campuses
- 16 specially designed rooms for BMTs
- Outpatient clinics with a full range of procedure, infusion and apheresis services
- On-site diagnostics, a marrow processing laboratory, surgical oncology and pharmacy services
- Two ^{131}I-MIBG treatment rooms
- A 13-chair day hospital (combination of private, semi-private and open-area chairs)

Dual-campus model

The Aflac Cancer Center offers a unique learning experience for fellows, providing rotations through our two hospital campuses—Egleston and Scottish Rite. Our dual-campus model allows fellows to interact with colleagues in private and academic settings, affording them a real-world training experience. Additionally, our model contributes to some of the country's largest pediatric patient volumes, exposing fellows to more educational cases and greater research opportunities.

While physical locations may be different, our units operate under the same clinical practice standards and use the same electronic medical records, allowing consistency across the two campuses. Video conferencing also effectively links both campuses for meetings. Fellows will be on service and on call at one campus at a time to alleviate travel between campuses.

"The two-campus model provides more depth to a fellow's clinical experience. I feel that our learning is enhanced by exposure to the academic and private practice settings."

–Jonathan Metts, MD

research

In conjunction with Emory University and the Winship Cancer Institute, the Aflac Cancer Center is committed to excellence and innovation in pediatric cancer and blood disorders research. Our rapidly growing research program includes physicians and PhDs studying BMT, brain tumors, cancer survivorship, leukemia and lymphoma, solid tumors, hemostasis and thrombosis, sickle cell disease, gene therapy and transfusion medicine.

- Our program conducts innovative laboratory research that focuses on gene therapy, molecular therapy, cell signaling, nanomedicine and genomics.
- We received a $9.5 million grant from the National Heart Lung and Blood Institute for bench-to-bedside research to develop treatments that could stem or stop acute chest syndrome in sickle cell disease patients—a major cause of mortality among those with sickle cell disease.
- We received a $1 million, four-year Exceptional, Unconventional Research Enabling Knowledge Acceleration grant, and our researchers and engineers are looking at a novel bioengineering solution aimed at pediatric brain tumors that could someday help eradicate almost any kind of tumor.
- As one of the first established National Institutes of Health (NIH) K12- and K30-sponsored clinical research training facilities, Emory University is part of the Clinical and Translational Science Award granted by the NIH.
- Our patients have access to more than 400 clinical studies, affording them access to some of the most novel treatment options in the country.
- We have ranked among the top 5 in the country for COG therapeutic clinical trial enrollment since 2015.*
- We have 14 faculty members who are current or former COG study chairs or disease committee members, ensuring state-of-the-art care, as well as committee opportunities for graduating fellows.
- We are members of the NIH clinical trials network for hemostasis, transfusion medicine and sickle cell disease.
- Through our robust Developmental Therapeutics (DevT) Program, we offer clinical trials related to a number of cancers and blood disorders.
- We are one of only 21 centers nationwide that is a member of the COG Phase I and Pilot Consortium.
- Multiple investigator-initiated trials are done within our own institution, as well as collaboratively with others throughout North America. The program offers enrollment in exclusive Phase I and Phase II studies for neuroblastoma and other cancers through our participation in collaborative research consortiums, such as Therapeutic Advances in Childhood Leukemia, Pediatric Oncology Experimental Therapeutics Investigator's Consortium and New Approaches to Neuroblastoma Therapy.
- We are one of 11 centers nationwide that is a member of the Pediatric Brain Tumor Consortium.

One of the largest pediatric clinical trial programs in the country*

2017 statistics:

- New cancer cases: 450-plus
- Active sickle cell disease patients: 1,916
- Bleeding disorders patients: 451
- BMT cases: 77
- Outpatient visits: 32,612
- Inpatient days: 18,401

** COG Institutional Report Card*

our team and interests

Leadership

Division Director
Douglas K. Graham, MD, PhD
Professor and Director, Aflac Cancer and Blood Disorders Center,
Children's Healthcare of Atlanta

Dr. Graham is an NIH investigator with an active laboratory focusing on developing novel therapeutics for pediatric cancer, recently validating MerTK as a novel cancer agent in leukemia, melanoma, non-small cell lung cancer and glioblastoma. He has served in multiple leadership roles with the American Society of Pediatric Hematology/Oncology and has an appointment as a full member of the NIH Molecular and Cellular Hematology Study Section.

Fellowship Program

William Woods, MD
Director, Fellowship Program
Aflac Cancer and Blood Disorders Center,
Children's Healthcare of Atlanta
Professor and Director Emeritus,
Emory University School of Medicine

Kathryn Sutton, MD
Associate Director, Fellowship Program
Aflac Cancer and Blood Disorders Center,
Children's Healthcare of Atlanta
Assistant Professor of Pediatrics,
Emory University School of Medicine

Glen Lew, MD
Associate Director, Fellowship Program
Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta
Associate Professor of Pediatrics, Emory University School of Medicine

BMT

Lakshmanan Krishnamurti, MD, Director of BMT: Newborn screening and counseling for hemoglobinopathies, novel approaches to hematopoietic stem cell transplantation for hemoglobinopathies, mechanisms of vascular complications of sickle cell disease and bioinformatics systems in clinical care and research in sickle cell disease

Kathryn Leung, MD, Clinical Director of BMT: Pediatric bone marrow or stem cell transplant for patients with bone marrow failure due to multiple causes and for patients with hemoglobinopathies

Shanmuganathan Chandrakasan, MD: Hematopoietic cell transplant/gene therapy for immune deficiency, immune deficiency, immune dysregulation and hemophagocytic lymphohistiocytosis (HLH), immunohematology and bone marrow failure, stem cell biology

Ann E. Haight, MD: BMT in sickle cell disease and other nonmalignant diseases, supportive care in BMT and infections in the immunocompromised host, and clinical research ethics

John Horan, MD: Nonmyeloablative transplant for sickle cell disease, graft-versus-host disease (GVHD) and outcomes research

Edwin Horwitz, MD, PhD: Transplantation of marrow cells and mesenchymal stromal cells (MSCs) to treat cancer and genetic disorders of childhood

Muna Qayed, MD, MSCR: Incorporation of novel agents into the treatment of relapsed solid tumors, improving current treatments for patients with high-risk disease, including autologous stem cell transplant and developing more effective prophylaxis and treatment against GVHD in patients undergoing allogeneic BMT

Elizabeth O. Stenger, MD: BMT for nonmalignant disease, tolerance and GVHD prevention and treatment

Benjamin Watkins, MD: Clinical trials and research in developing more effective prophylaxis and treatment against GVHD in patients undergoing allogeneic BMT

Hematology

General hematology

Jeanne M. Boudreaux, MD, Clinical Director of Hematology: Thalassemias, bone marrow failure syndromes, hemolytic anemias and white cell disorders

Staci Arnold, MD: Health outcomes, cost benefit analysis, comparative effectiveness research for sickle cell disease and bone marrow failure syndromes

Glaivy Batsuli, MD: Basic and translational research in hemophilia A and inhibitors

Carolyn M. Bennett, MD: Platelet disorders, including immune thrombocytopenic purpura (ITP)

Michael A. Briones, DO: Vascular anomalies, histiocytic disorders, general hematology and inherited bone marrow failure syndrome

Shanmuganathan Chandrakasan, MD: Hematopoietic cell transplant and gene therapy for immune deficiency, immune deficiency, immune dysregulation and HLH, immunohematology and bone marrow failure, stem cell biology

Satheesh Chonat, MD: Red cell enzyme and red membrane deficiencies

Kavita Patel, MD: Thrombosis treatment and prevention

Maa-Ohui Quarmyne, MbChB: Sickle cell disease and thalassemias, stroke prevention in sickle cell disease and outcomes in sickle cell disease

Marianne E. Yee, MD, MSc: Clinical research in sickle cell disease, hemoglobin disorders, transfusion therapy and BMT for patients with sickle cell disease

Hemophilia/thrombosis

Robert Sidonio Jr., MD, Clinical Director of Hemostasis and Thrombosis: von Willebrand disease, particularly in the setting of menorrhagia

Pete Lollar, MD, Research Director of Hemostasis: Development of novel recombinant Factor VIII molecules for use in preventing and treating hemophilia patients with inhibitors and basic research in biosynthesis and expression of Factor VIII

Glaivy Batsuli, MD: Basic and translational research in hemophilia A and inhibitors

Carolyn M. Bennett, MD: Platelet disorders, including ITP

Wei Deng, PhD: Protein interactions that contribute to the hemostasis and thrombosis to investigate how these interactions are disturbed in patients with bleeding disorders and to search for effective therapeutic approaches

Renhao Li, PhD: Development of novel reagents to improve bleeding diagnostics and platelet storage

Shannon Meeks, MD: Basic and translational research in hemophilia A and inhibitors

Kavita Patel, MD: Thrombosis treatment and prevention

Brian Petrich, PhD: Regulation of platelet integrin signaling in hemostasis, and thrombosis and cell adhesion mechanisms in vascular disease and thrombosis

Yingchun Wang, MD, PhD: Clinical basic and translational research in hemophilia and thrombosis

Gary Woods, MD: Venous thromboembolism, especially in chronic disease like sickle cell disease and pediatric heart disease, and coagulation disorders

Sickle cell disease

Clinton H. Joiner, MD, PhD, Director of Hematology: Red cell physiology, specifically cation transport and volume regulation and their perturbation in sickle cell disease

R. Clark Brown, MD, PhD, Clinical Director: Targeted therapies for thalassemia and sickle cell disease

Beatrice Gee, MD, Clinical Director: Clinical research in sickle cell disease

Marianne E. Yee, MD, MSc, Clinical Director: Clinical research in sickle cell disease, hemoglobin disorders, transfusion therapy and BMT for patients with sickle cell disease

Peter A. Lane, MD, Program Director: Newborn screening, health outcomes and clinical trials in sickle cell disease

David R. Archer, PhD: Hematopoietic stem cell transplant for genetic disease, particularly sickle cell disease and use of stem cells in regenerative medicine

Nitya Bakshi, MD: Pain in sickle cell disease, including psychophysical pain phenotyping in pediatric patients with sickle cell disease and development and validation of electronic pain diaries for children with sickle cell disease

Carlton D. Dampier, MD: Clinical trials in sickle cell disease, measurement science of patient- and parent-reported outcomes and symptom management in sickle cell disease, particularly pain

Elaissa Hardy, PhD: Effects of applied electricity with hemostasis

Anne G. James-Herry, MD: Clinical trials in sickle cell disease, comprehensive sickle cell disease and specialty clinics, particularly pulmonary and GI- and age-based clinics

Hyacinth Hyacinth, MD, PhD: Stroke and other neurovascular complications of sickle cell disease

Wilbur A. Lam, MD, PhD: Development and application of novel bioengineering technologies to study, diagnose and treat hematologic disorders

David Myers, PhD: Developing novel microsystems for clinical diagnosis and high-throughput single cell studies

Tamara N. New, MD: Clinical trials in sickle cell disease, interest in chronic pain, pulmonary complications and global impact of sickle cell in economically poor countries

Maa-Ohui Quarmyne, MbChB: Sickle cell disease and thalassemias, stroke prevention in sickle cell disease and outcomes in sickle cell disease

Amy Tang, MD: Sickle cell anemia and transfusional iron overload

Transfusion medicine

Cassandra D. Josephson, MD: Clinical transfusion medicine and blood safety in hemophilia, sickle cell disease, neonatology and open heart surgery

Oncology

Leukemia and lymphoma

Sharon Castellino, MD, Director of Leukemia and Lymphoma: Hodgkin lymphoma and survivorship

Daniel Wechsler, MD, PhD, Director of Oncology: Infant leukemias, pathogenesis of poor prognosis CALM-associated leukemias and MYC antagonism in neuroblastoma

Douglas K. Graham, MD, PhD, Division Director: Developing novel therapeutics for pediatric cancer, recently validating MerTK as a novel cancer agent in leukemia, melanoma, nonsmall cell lung cancer and glioblastoma

Frank G. Keller, MD, Clinical Director of Leukemia: Principle investigator of COG trial for low-risk Hodgkin's disease and clinical trials in Hodgkin's disease, non-Hodgkin's lymphoma and leukemia

Kevin D. Bunting, PhD, Research Director of Leukemia and Lymphoma: Studies of normal cytokine signaling in hematopoiesis and dysregulated signaling associated with inflammation and cancer

D. John Bergsagel, MD: Clinical trials in leukemia and lymphoma

Deborah DeRyckere, PhD: Preclinical development of novel small molecule MerTK inhibitors for oncology applications, TAM-family receptor tyrosine signaling and biology, murine xenograft models of acute leukemia

Kavita Dhodapkar, MD, PhD: Mechanisms of immune regulation, in the context of autoimmunity as well as tumor immunity, in-vivo effects of immune checkpoint blocking therapies, including the role for B cells in development of autoimmunity following treatment with these agents, methods to boost anti-tumor immunity using dendritic cells

Lubing Gu, MD: Molecular mechanisms of drug resistance in childhood cancer and leukemia

Curtis Henry, PhD: Research focuses on understanding how chronic inflammation associated with aging and obesity impacts leukemia development and therapeutic responses

Glen Lew, MD: Study chair of COG Phase III trial for relapsed acute lymphoblastic leukemia (ALL) and etiology, treatment and outcomes in childhood ALL

Tamara Miller, MD, MSCE: Leukemia and lymphoma, general oncology and adverse events

Katherine Minson, MD: Novel therapeutic targets in AML

Melinda Pauly, MD: Relationship of the BCL-2 family of proteins within the intrinsic apoptotic pathway to members of the autophagy pathway

Christopher Porter, MD: Cancer genetics and leukemia research

Cheng-Kui Qu, MD, PhD: Cell signaling and metabolic regulation of hematopoietic stem cells focusing on the role of protein and lipid phosphatases in normal hematopoietic cell development and leukemogenesis, and development of novel therapeutics for phosphatases-associated blood disorders, such as juvenile myelomonocytic leukemia

Sunil Raikar, MD: Development of novel chimeric antigen receptor (CAR) natural killer cells against T-cell malignancies

Himalee Sabnis, MD, MS: Biology of acute myeloid leukemia (AML), signaling pathways in leukemic cells and new therapeutic agents in AML

Zhengqi Wang, PhD: Study of STAT5 and its function in signaling mechanisms in leukemogenesis, hematopoietic stem cell biology and transplant

William G. Woods, MD: Clinical trials within COG in myeloid leukemia

Dan Yan, PhD: The role of MerTK on human non-small-cell lung cancer

Muxiang Zhou, MD: Signaling pathways and regulators of apoptosis relating to drug resistance in ALL

Palliative care

Katharine Brock, MD, MS: Clinical research in palliative care, assessing, and improving access and quality of pediatric palliative care within oncology, and the metrics and outcomes associated with a pediatric supportive care clinic

Solid tumors

Thomas A. Olson, MD, Clinical Director of Solid Tumors: Committee chair for COG germ cell disease, clinical trials in germ cell tumors, retinoblastoma and bone tumors

Thomas Cash, MD, MSc: Outcomes and epidemiology in rare pediatric tumors; the role of ezrin and tumor necrosis in patients with Ewing Sarcoma, and innovative therapy and Phase I and II trials

Bradley A. George, MD: Solid tumors and histiocytosis

Kelly Goldsmith, MD: Basic and translational research of neuroblastoma, with a primary focus on mechanisms of therapy resistance

Sarah Mitchell, MD: Solid tumors and rare tumors, underlying hereditary cancer syndrome

Robert Schnepp, MD, PhD: Research with a major emphasis on high-risk neuroblastoma and rhabdomyosarcoma employing a number of techniques, including cell and molecular biology, animal modeling, interrogation of genomic datasets with clinical annotation and functional genomics

Kathryn Sutton, MD: Clinical researcher in solid tumors, including sarcomas, rare tumors and histiocytosis

Neuro-oncology

Tobey J. MacDonald, MD, Director of Neuro-oncology: Basic and translational research of childhood brain tumors with a primary research focus on the metastasis and role of platelet-derived growth factor receptor (PDGFR) signaling

Dolly Aguilera, MD: Development of Phase I and II clinical trials for children with recurrent brain tumors

Robert C. Castellino, MD: Pediatric neuro-oncology, interactions between p53/Hedgehog/and PI-3 Kinase cell signaling in neuronal development, brain tumor development or progression, and as targets for drug development

Delores Hambardzumyan, PhD: Investigating the role of the brain microenvironment in how it contributes to pediatric and adult glioblastoma growth and response to therapy

Anna J. Janss, MD, PhD: Phase I COG clinical trials and innovative therapeutics for brain tumors

Anna M. Kenney, PhD: How Sonic hedgehog and interacting signal transduction pathways control normal and neoplastic development within the cerebellum

Claire M. Mazewski, MD: Principal investigator of COG high-risk medulloblastoma trial for young children, clinical trials, innovative therapeutics and late effects studies for children with brain tumors

Hospitalists

Joanna Newton, MD: Racial and ethnic disparities in pediatric AML outcomes, and expression of CD36 and the presence of cytoplasmic granules in blasts predicts poor prognosis in children with B-lymphoblastic leukemia

Psychology and neuropsychology

James Klosky, PhD, Director of Psychology: Childhood cancer psychology

Grace Fong, PhD: Acquired brain injury and clinical trials for late effects

Lisa Ingerski, PhD: Childhood psychology

Alcuin Johnson, PhD: Acquired brain injury, transition to adult care and motivational interviewing

Jordan Marchak, PhD: Childhood cancer survivorship and transition to adult care

Laura Mee, PhD: Childhood cancer psychology issues with transplant patients, pain management and coping with chronic medical conditions

Jennifer Lee, PhD: Childhood cancer psychology

Soumitri Sil, PhD: Research on pediatric pain management focused on the development and evaluation of behavioral interventions to promote the health and functioning of children and adolescents with complex chronic pain conditions

Beth Thompson, PsyD: Pain management, pica and coping with chronic illness

Angela Vaz, PhD: Consultation liaison in pediatric psycho-oncology, parent-child coping with pediatric chronic illness, and chronic stress and bereavement

Cancer survivorship

Karen Effinger, MD, Clinical Director of Survivorship: Physical and psychosocial functioning in children, adolescents and young adults after cancer treatment with a particular focus in cardiovascular health, health risk behaviors, wellness and physical functioning

Lillian R. Meacham, MD, Medical Director of Survivorship: Childhood Cancer Survivor Study, educating survivors and providers about survivor care, and endocrine late effects in oncology patients

Ann C. Mertens, PhD, Research Director of Survivorship: Childhood and adolescent cancer survivorship

Briana C. Patterson, MD: Late effects of cancer therapy in brain tumor patients and endocrine problems following cancer treatment

Cell and gene therapy

Muna Qayed, MD, MSCR, Clinical Director of Cell and Gene Therapy: Incorporation of novel agents into the treatment of relapsed solid tumors, improving current treatments for patients with high-risk disease, including autologous stem cell transplant and developing more effective prophylaxis and treatment against GVHD in patients undergoing allogeneic BMT

H. Trent Spencer, PhD, Program Director of Gene Therapy: Developing and implementing cell and gene therapy for the treatment of childhood cancer and inherited diseases, with a specific emphasis on the genetic engineering of hematopoietic stem cells

Christopher B. Doering, PhD: Development of modified blood coagulation factors and implementation in gene transfer-based therapies

Lakshmanan Krishnamurti, MD: Newborn screening and counseling for hemoglobinopathies; novel approaches to hematopoietic stem cell transplantation for hemoglobinopathies; mechanisms of vascular complications of sickle cell disease; bioinformatics systems in clinical care and research in sickle cell disease

Renhao Li, PhD: Development of novel reagents to improve bleeding diagnostics and platelet storage

Himalee Sabnis, MD, MS: Biology of AML, signaling pathways in leukemic cells and new therapeutic agents in AML

Elizabeth O. Stenger, MD: BMT for nonmalignant disease, tolerance and GVHD prevention and treatment

Yingchun Wang, MD, PhD: Basic and translational research in hemophilia and thrombosis

Karen Wasilewski, MD, MSc: Bone sarcomas, adolescent and young adult oncology, supportive care/ cancer control studies and transition of care

Developmental therapeutics

Jason Fangusaro, MD, Director of Developmental Therapeutics: Development of early phase clinical trials, novel therapeutics and relevant biologic correlates in an effort to improve survival outcomes and minimize toxicities. Within pediatric brain tumors, his research has focused on three main areas: low grade gliomas, central nervous system germ cell tumors and immunotherapy

Melinda Pauly, MD, Clinical Director of Developmental Therapeutics: Relationship of the BCL-2 family of proteins within the intrinsic apoptotic pathway to members of the autophagy pathway

Dolly Aguilera, MD: Development of Phase I and II clinical trials for children with recurrent brain tumors

Thomas Cash, MD, MSc: Outcomes and epidemiology in rare pediatric tumors; the role of ezrin and tumor necrosis in patients with Ewing sarcoma; innovative therapy and Phase I and Phase II trials

Robert C. Castellino, MD: Pediatric neuro-oncology, interactions between p53/Hedgehog/and PI-3 Kinase cell signaling in neuronal development, brain tumor development or progression, and as targets for drug development

Kelly Goldsmith, MD: Basic and translational research of neuroblastoma, with a primary focus on mechanisms of therapy resistance

Tobey J. MacDonald, MD: Basic and translational research of childhood brain tumors with a primary research focus on the metastasis and role of PDGFR signaling

Himalee Sabnis, MD, MS: Biology of AML, signaling pathways in leukemic cells and new therapeutic agents in AML

Ranked among the fastest-growing metro areas in the country,* Atlanta combines Southern hospitality with the amenities of any world-class city. More than 6.5 million metro Atlanta residents enjoy the city's rich history and cultural diversity. Whether you are a sports fanatic, history buff or have a love of the arts, Atlanta offers something for everyone.

Why Atlanta?

- Cost of living is less expensive than other major cities**
- Hartsfield-Jackson Atlanta International Airport is the world's busiest airport
- Atlanta is within a two-hour flight of 80 percent of all U.S. cities
- Twenty-six companies headquartered in metro Atlanta are among the 2018 Fortune 1000, of which 15 are also ranked in the 2018 Fortune 500
- Museums, theaters and eclectic shopping areas
- Professional sports teams, including the Atlanta Falcons, Atlanta Braves, Atlanta Hawks and Atlanta United
- Vast number of restaurant options, including a wealth of ethnic cuisines
- Seasonal climate suitable for outdoor activities year-round
- Within driving distance of the mountains and ocean

contact us

Visit choa.org/aflacfellowship for more information.

Email Angie Graves at angie.graves@emory.edu.
Email William Woods, MD, at william.woods@choa.org.

All applications are accepted through ERAS. A requirements checklist is available online.

*forbes.com
**metroatlantachamber.com

Hughes Spalding is owned by Grady Health System and managed by HSOC Inc., an affiliate of Children's Healthcare of Atlanta.

Some physicians and affiliated healthcare professionals on the Children's Healthcare of Atlanta team are independent providers and are not our employees.

Aflac
Cancer & Blood Disorders Center
CHILDREN'S HEALTHCARE OF ATLANTA